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Abstract 
Kaposi sarcoma-associated herpesvirus (KSHV) ORF57, also known as Mta (mRNA transcript 
accumulation), enhances viral intron-less transcript accumulation and promotes splicing of 
intron-containing viral RNA transcripts. In this study, we identified KSHV PAN, a long 
non-coding polyadenylated nuclear RNA as a main target of ORF57 by a genome-wide CLIP 
(cross-linking and immunoprecipitation) approach. KSHV genome lacking ORF57 expresses 
only a minimal amount of PAN. In cotransfection experiments, ORF57 alone increased PAN 
expression by 20-30-fold when compared to vector control. This accumulation function of 
ORF57 was dependent on a structured RNA element in the 5' PAN, named MRE (Mta re-
sponsive element), but not much so on an ENE (expression and nuclear retention element) in 
the 3' PAN previously reported by other studies. We showed that the major function of the 
5' PAN MRE is increasing the RNA half-life of PAN in the presence of ORF57. Further mu-
tational analyses revealed a core motif consisting of 9 nucleotides in the MRE-II , which is 
responsible for ORF57 interaction and function. The 9-nt core in the MRE-II also binds cellular 
PABPC1, but not the E1B-AP5 which binds another region of the MRE-II. In addition, we found 
that PAN RNA is partially exportable in the presence of ORF57. Together, our data provide 
compelling evidence as to how ORF57 functions to accumulate a non-coding viral RNA in the 
course of virus lytic infection. 
Key words: KSHV, long non-coding RNA, ORF57, PAN, RNA stability, RNA accumulation, 
PABPC1, E1B-AP5 
Introduction 
Kaposi's sarcoma-associated herpesvirus 
(KSHV), also known as human herpesvirus 8 (HHV8), 
belongs to the gamma herpesvirus family and is the 
causative agent for Kaposi's sarcoma, the most com-
mon AIDS-associated cancer [1-3]. KSHV is also asso-
ciated with other lymphotropic malignancies, such as 
primary effusion lymphoma (PEL) and multicentric 
Castleman's disease [4,5]. Similar to other herpesvi-
ruses, KSHV undergoes two distinguishable viral life 
cycles: latency and a lytic replication. However, and 
unlike other viruses, the KSHV latent program does 
not efficiently immortalize virus infected cells [6,7]. 
Experimental evidence also indicates that viral factors 
encoded during the lytic cycle, such as paracrine sig-
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nals [8], or viral proteins, like the G protein-coupled 
receptor (vGPCR) [9,10], might supply the inflamma-
tory and angiogenic components required for cell 
transformation [7].  
 Given the importance of the KSHV lytic cycle, 
we are interested in the mechanisms underlying the 
regulation of viral lytic gene expression. During the 
lytic cycle, KSHV expresses two main regulatory 
proteins: ORF50 (Rta, replication and transcription 
activator) which initiates transcription of viral lytic 
genes [11,12] and ORF57 (Mta, mRNA transcript ac-
cumulation), a multifunctional protein that promotes 
the accumulation of viral intron-less transcripts 
[13-17] and stimulates intron removal of viral in-
tron-containing RNAs [18,19]. The intron removal 
function of ORF57 is especially important for the vi-
rus, as pre-mRNA lacking appropriate posttranscrip-
tional processing is less stable than its properly pro-
cessed functional counterpart [20]. Lytic KSHV repli-
cation also promotes widespread shutoff of cellular 
gene expression by hyperadenylation and nuclear 
retention of host mRNA which leads to enhancement 
of cellular mRNA turnover [21-23]. Thus, it is no sur-
prise that KSHV has evolved mechanisms for regu-
lating the ORF57-mediated post-transcriptional viral 
RNA processing and accumulation. To understand 
how ORF57 functions in host cells is a key step to de-
termine how KSHV ensures the expression of its own 
genes, while also shutting-off host gene expression 
during virus lytic infection. Previously, we have de-
scribed a mechanism as to how ORF57 stimulates the 
expression of intron-containing viral RNA transcripts 
in [18]. However, it remains unclear how ORF57 ac-
cumulates intron-less viral RNAs, and whether the 
accumulation is mediated by interfering with nuclear 
export [13,16,24-26].  
 Recently, we conducted a genome-wide CLIP 
(UV-crosslinking and immunoprecipitation) assay 
from B cells with KSHV lytic infection and identified 
11 viral transcripts as putative ORF57 targets [27]. 
One of those targets was vIL-6, which stimulates cell 
proliferation during KSHV infection [8]. We found 
that vIL-6 RNA contains an ORF57 responsive ele-
ment. ORF57 binding to this element in vIL-6 RNA 
stabilizes vIL-6 RNA and promotes vIL-6 translation 
by interfering with miR-1293-mediated vIL-6 mRNA 
repression [27]. 
 Subsequently, we identified PAN RNA (poly-
adenylated nuclear RNA) as a major target of ORF57 
and, therefore, became interested in whether ORF57 is 
also involved in modulating PAN RNA metabolism. 
PAN is the most abundant viral transcript, constitut-
ing ~80% of all polyadenylated transcripts in a cell 
with lytic KSHV infection [28,29]. PAN is a long 
non-coding, polyadenylated nuclear RNA transcribed 
by RNA polymerase II [28-30] which differs from EBV 
non-coding, small nuclear RNAs, EBER-1 and EBER-2 
transcribed by RNA polymerase III [31]. In the nu-
cleus, PAN forms a speckled pattern typical of U 
snRNAs and colocalizes with Sm protein [28,32]. We, 
along with other groups, have shown that ORF57 
promotes PAN RNA accumulation [14,33]. Previous 
studies showed that PAN RNA stability in the ab-
sence of ORF57 seems to be dependent on the activity 
of a cis-acting 79-nucleotide (nt) RNA element located 
in the 3' PAN, called ENE (expression and nuclear 
retention element)[34-37]. In the absence of the ENE, 
PAN’s stability appears to rely on ORF57 binding to a 
5' motif [38]. In this report, we identified a 9-nt core 
motif in the 5' PAN region that is responsible for 
ORF57-mediated PAN accumulation. The element 
containing the core motif is designated as MRE (Mta 
responsive element) and its major function is in-
creasing the half-life of PAN RNA in the presence of 
ORF57. In contrast, the ENE plays only a small role in 
ORF57-mediated accumulation of PAN. We found 
that the PAN MRE interacts with ORF57 and cellular 
proteins PABPC1 and E1B-AP5.  
Materials and methods 
Cells 
 Human HEK293 and HeLa cells were cultivated 
in Dulbecco's modified Eagle medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine 
serum (FBS, HyClone, Logan, UT), 2 mM 
L-glutamine, 100 U/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen). HEK293 cell lines stably 
harboring a KSHV wt genome (Bac36-wt) or an 
ORF57-null KSHV genome (Bac36-Δ57) [33] were in-
duced with 1 mM valproate (VA) for lytic infection. 
JSC-1 cells (KSHV+/EBV+) and BCBL1 cells (KSHV+) 
were grown in RPMI 1640 containing 10% FBS and 
were induced, respectively, with sodium butyrate 
(Bu, 3 mM) and VA (1 mM) for lytic infection. TREx 
BCBL1-vector and TREx BCBL1-Rta cells [39] were 
cultivated in RPMI 1640 supplemented with 10% FBS 
and hygromycin B (50 μg/ml). To induce the expres-
sion of KSHV lytic genes, TREx BCBL1-Rta or TREx 
BCBL1-vector (a negative control) cells at 5 x 105 
cells/ml were seeded and cultivated for 24 h in the 
presence of 1μg/ml of doxycycline (Dox). 
Mammalian expression vectors 
 Mammalian expression vectors pVM7 (for 
FLAG-tagged ORF57), pVM8 (for GFP-tagged ORF57) 
and pVM36 (for GFP-tagged inactive ORF57 with 
point mutations in NLS2+3 or ORF57 mtNLS2+3) 
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were described in our previous report [13]. KSHV 
ORF50 (Rta) expression vector has been used in our 
laboratory for various studies [33,40]. Other plasmids 
used in this study and the oligos and strategy used for 
their construction are listed in Supplementary Mate-
rial: Table S1. See oligo sequences in Supplementary 
Material: Table S2. Overlapped PCR for mutant con-
structions was performed as described [41].  
Transient transfection assay 
 Cotransfection of expression vectors PAN (wt 
and mutants), vGPCR, or K5 was performed in 
HEK293 or HeLa cells (5 x105 cells/well) in a six-well 
plate, with 1 μg of individual vector together with 0.2 
μg (5:1 ratio) of pVM7 (ORF57-FLAG fusion) [13] or 
an empty pFLAG-CMV-5.1 vector using Lipofec-
tamine 2000 (Invitrogen).  
Western blot 
 Protein samples for Western blotting were pre-
pared by direct lysis of the cells in 0.5 ml of 2X SDS 
sample buffer (Quality Biological, Inc., Gathersburg, 
MD) plus 10% 2-mercaptoethanol. Samples were 
boiled and resolved in a 4%-12% SDS-polyacrylamide 
gel by electrophoresis. The following antibodies were 
used in Western blot analyses: a rabbit polyclonal 
anti-ORF57 antibody [33](1:3,000 dilution), mouse 
monoclonal anti-ORF57 antibody (unpublished data, 
used at a dilution of 1:1,000), rabbit polyclonal an-
ti-PABPC1 (1:700, Abcam ab21060), and rabbit poly-
clonal anti-E1B-AP5 (1:1,000, ProteinTech Group 
0578-1-AP, Chicago, IL), together with corresponding 
peroxidase-conjugated secondary antibodies 
(1:10,000, Sigma). The signal on the western blot was 
detected with West Pico chemiluminiscence substrate 
(Pierce, Rockford, IL).  
RNA preparation and Northern blot 
 Total cell RNA samples were prepared 24 or 48 h 
after transfection (HEK293, HeLa) or after induction 
(B cells) by the addition of 1 ml of TRIzol reagent ac-
cording to the TRIzol protocol (Invitrogen). Cyto-
plasmic and nuclear total RNAs were fractionated as 
described [13]. RNA (~5 μg) was separated in a 1% 
agarose gel and analyzed by Northern blotting [13]. 
PAN, K5 and vGPCR RNAs expressed from individ-
ual plasmids were detected with 2 × 106 cpm of a 
γ-32P-labeled T7 probe oZMZ243 (see Supplementary 
Material: Table S2 for sequence details). PAN was also 
detected with a PAN-specific probe oJM7 (Supple-
mentary Material: Table S2). ORF57 was detected with 
an oligo probe oVM11 (Supplementary Material: Ta-
ble S2). The hybridization signal was captured using a 
Molecular Dynamics PhosphorImager Storm 860 and 
analyzed with ImageQuant software. 
CLIP and RT-PCR 
 CLIP assays were conducted as described [27]. 
RT-PCR was performed by using a PAN-specific 
primer pair oVM52 and oJM7 on DNase-treated total 
RNA extracted from the CLIP complexes obtained 
with an anti-ORF57 antibody or rabbit IgG (a negative 
control). 
Luciferase Assays 
 To evaluate luciferase activity in HEK293 cells, 
2.5 x105 cells were grown in 24-well plates and trans-
fected with 50 ng of each firefly luciferase reporter 
plasmid (pMIR-REPORT-Luciferase reporter or its 
derived pJM19, pJM43 and pJM44, see Supplementary 
Material: Table S1 for details) together with 10 ng of 
Renilla luciferase reporter (pRL-TS) [42] using 
Lipofectamine 2000. Cells were harvested in dual lu-
ciferase assay 1x lysis buffer (Promega, Madison, WI). 
To evaluate activity in TREx BCBL1 cells, 2.5 x105 
TREx BCBL1-Rta cells were grown in 24-well plates 
for 24 h and the reactivated by addition of Dox (1 
μg/ml). One hour after Dox addition, the cells were 
transfected with 100 ng of each firefly and Renilla lu-
ciferase reporter plasmid (psiCHECK2 or its derived 
pJM47, pJM48, pJM49, pJM50 and pJM51, see Sup-
plementary Material: Table S1 for details) using 
FugeneHD transfection agent (Roche Diagnostics, 
Indianapolis, IN). 24 h after transfection, the cells 
were harvested in dual luciferase assay 1x lysis buffer. 
The volume of the buffer added was adjusted ac-
cording to cell number of each testing condition in 
order to obtain an equal amount of protein levels of 
induced vs un-induced conditions. Luciferase activity 
measured from cell lysate supernatant using a Glo-
Max®-Multi Microplate Multimode Reader 
(Promega) was expressed in ratios of firefly to Renilla 
(F/R for HEK293 cells) or Renilla to firefly (R/F for 
TREx BCBL1-Rta cells). 
 We performed a mixed model ANOVA on lu-
ciferase activities (Fig. 5D). An eight level treatment 
group (4 plasmids x 2 treatments) was used as the 
fixed effect. Two-tailed p-values were determined 
after adjusting for the number of comparisons per-
formed, using a standard method (due to Holm). Re-
siduals were examined for normality and homogene-
ity and were partitioned if found to be heterogeneous.  
RNA-protein pulldown assay 
 Total cell extracts used in RNA pulldown assays 
were prepared from ~5 x 106 of TREx BCBL1-Rta or 
-vector cells which were reactivated by Dox (1 μg/ml) 
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for 24 h. The cells were harvested by centrifugation at 
800 x g at 4oC for 5 min, washed twice with 1 x PBS 
and resuspended in 500 μl (Rta cells) or 1000 μl (vector 
cells) of 1x RIPA buffer containing protease inhibitor 
(Complete Mini EDTA-free Protease Inhibitor Cock-
tail, 1x, Roche). The samples were incubated for 10 
min on ice, briefly sonicated (10 times at level 4), and 
centrifuged for 25 min at 10,000 x g at 4oC. The extract 
supernatant ready for RNA pulldown was aliquoted 
and stored at -20oC. 
 RNA pulldown assay using biotinylated RNA 
oligomers was performed as described [27,43]. The 
following RNA oligos used in the pulldowns and 
schematized in Fig. 6A were oJM32, oJM33, oJM34, 
oJM35 and oJM68 (see sequence details in Supple-
mentary Material: Table S2). RNA oligos oNP41 and 
oNP42 derived from vIL-6 RNA served, respectively, 
as a negative and positive control for ORF57 binding 
[27]. The proteins in the pulldowns were analyzed by 
Western blot. Alternatively, the proteins resolved in a 
4%-12% SDS-PAGE gel were silver-stained using Sil-
verQuest™ Silver Staining Kit (Invitrogen) and the 
corresponding proteins in a separate gel without sil-
ver staining were gel-purified and identified using 
Nano LC-MS/MS peptide sequencing technology 
(ProtTech, Inc., Norristown, PA). 
RNA stability assay 
 PAN decay was analyzed in HEK293 cells tran-
siently transfected with individual PAN expression 
plasmids in the presence or absence of ORF57. Since 
PAN is expressed at a very low level in the absence of 
ORF57, HEK293 cells (1x 106) in 60-mm dishes were 
cotransfected using FuGene HD (Roche) with 4 μg of a 
wt PAN expression plasmid plus 800 ng of an empty 
pFLAG-CMV-5.1 vector, 20-times more PAN expres-
sion vector in the absence of ORF57 than its transfec-
tion in a 24-well plate in the presence of ORF57. Re-
al-time PCR for PAN and GAPDH RNA was carried 
out on the cDNA in duplicates as described previ-
ously [26]. GAPDH RNA levels remained constant in 
the course of the experiments by normalization with 
β-actin RNA. The following PAN TaqMan primers 
from IDT (Coralville, IA) were used: PAN Probe; PAN 
primer 1; PAN primer 2 (Supplementary Material: 
Table S2). The relative expression of PAN was deter-
mined using 2-ΔΔCT method [27,44,45] and converted 
to percentage, with the amount at time zero of acti-
nommycin D (act. D) addition as 100 %. The RNA 
decay represents remaining RNA (%) over the time 
zero in the presence or absence of ORF57. A 
non-linear regression analysis on the raw data was 
performed and applied to an exponential decay mod-
el [Fold Percent = α*exp(β*time)], where α (alpha) is 
the intercept when time = 0, and β (beta) is the decay 
rate. Alpha was constrained to be equal to 100% 
(α=100%), and beta to be less than or equal to zero 
(β<=0). Comparison of beta parameter estimates be-
tween the treatments was performed by using a 
model with a dummy variable (model based 
two-tailed p-value via t-test). The half-life for each 
treatment was estimated by letting the fold percent 
equal 50% and solving for time.  
Results 
PAN is associated with ORF57 in B cells with 
KSHV lytic infection and responds to ORF57 
function 
 Among 11 potential RNA targets of ORF57 
identified in B cells with KSHV lytic infection by an 
anti-ORF57 CLIP assay [27], PAN RNA sequences 
were pulled down more than 90 times, listing the 
PAN as one of the most prominent targets in the 
ORF57 CLIP assays. Considering PAN is the most 
abundant KSHV RNA constituting ~80% of all poly-
adenylated transcripts in a cell with lytic KSHV infec-
tion [28,29], the high frequency of PAN sequences 
identified in the ORF57 CLIP assays might simply 
reflect the abundance of PAN in an RNA pool of the 
KSHV-infected B cells. However, when aligned 
against the KSHV genome, the isolated PAN se-
quences were clustered mainly at the 5'-half (nt 
28667-28750 with 16 sequence tags) and 3'-half (nt 
29544-29658 with 43 sequence tags) of PAN (NCBI 
accession no.: U75698) [46], along with a fewer se-
quence tags clustering in the middle regions of PAN 
[Supplementary Material: Fig. S1, also see Supple-
mentary Material: Table S1 in the reference [27]], in-
dicating a sequence-specific PAN association of 
ORF57 in B cells with KSHV lytic infection. Interest-
ingly, the PAN 3' region interacting with ORF57 en-
compasses a structured ENE (expression and nuclear 
retention element) previously identified for the nu-
clear abundance of PAN [34] through its U-rich in-
ternal loop interacting with the PAN poly (A) tail [36]. 
 The interaction between PAN RNA and ORF57 
in B cells with KSHV lytic infection was then verified 
using CLIP/RT-PCR, by which PAN RNA was spe-
cifically pulled down with an anti-ORF57 antibody, 
but not an IgG control (Fig. 1A). Previous studies have 
demonstrated a role of ORF57 in PAN expression 
[14,33]. Consistent with these findings, we observed 
that PAN expression was increased during lytic 
KSHV induction in two B cell lines BCBL-1 (Fig. 1B, 
compare lane 1 to lane 2) and JSC-1 (Fig 1B, compare 
lane 5 to lane 6).  
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Fig. 1. PAN expression depends on viral ORF57. (A) 
ORF57 binds PAN RNA during lytic KSHV infection. 
RT-PCR was performed by using a PAN-specific primer pair 
on total RNA isolated from the CLIP complexes obtained 
with an anti-ORF57 antibody from butyrate-treated JSC-1 
cells. (B) PAN expression depends on ORF57 during lytic 
KSHV infection. Total RNA obtained from BCBL-1 and 
JSC-1 cells induced with butyrate (Bu, 3 mM) or from Bac36 
cells with a wild-type KSHV genome (Bac36 wt) and 
Bac36-Δ57 cells with an ORF57-null KSHV genome [33] 
induced with VA (1 mM) was examined by Northern blot 
for PAN RNA with a PAN-specific probe oJM7. GAPDH 
RNA served as a loading control. (C) ORF57 enhances PAN 
accumulation at the posttranscriptional level. Total RNA 
from HEK293 cells transfected with an expression vector of 
PAN, K5 or vGPCR (see diagrams) or an empty pcDNA3 
vector, together with a FLAG-tagged ORF57 (+) or an 
empty FLAG vector (-) was examined by Northern blot 
with a T7 probe for expression of PAN, K5 or vGPCR. (D) 
ORF57 inactive mutant (mtNLS2+3) is unable to enhance 
PAN expression. Total RNA from HEK293 cells transfected 
with a PAN expression vector together with a GFP-tagged 
ORF57 wt (ORF57 wild type), GFP-tagged ORF57 inactive 
mutant (mtNLS2+3) [13] or GFP empty vector pEGFP-N1 
was examined by Northern blot for PAN RNA. 
 
 
This increase of PAN expression during lytic 
KSHV infection, in the context of KSHV genome, is 
dependent on ORF57 expression. As shown in Fig. 1B, 
Bac36-wt cells with stable transfection of a wt KSHV 
genome responded to viral lytic induction by VA for 
PAN expression, but Bac36-Δ57 cells with stable 
transfection of an ORF57-null KSHV genome did not 
(compare lane 3 to lane 4). By cotransfection analyses 
of HEK293 cells, we further demonstrated that PAN 
was the most prominent responder (~35-fold increase) 
to ORF57 in the absence of other viral proteins when 
comparing with KSHV K5 and vGPCR (Fig. 1C), alt-
hough expression of all three tested genes in the vec-
tor were driven by the same cytomegalovirus (CMV) 
immediate-early promoter. Both KSHV K5 and 
vGPCR did not interact with ORF57 in our CLIP as-
says and were previously shown as a non-responder 
to ORF57 [14]. Consistently, we found only a slight 
increase of K5 (~5 fold) and vGPCR (~3 fold) in the 
presence of ORF57 in our cotransfection assays (Fig. 
1C). Together, these data suggest that ORF57 regu-
lates PAN expression at the posttranscriptional level. 
When an ORF57 inactive mutant (a NLS2+3 mutant) 
[13] was included for comparison, increased PAN 
expression was found in the cotransfection with wt 
ORF57, but not with the mt ORF57 (Fig. 1D). Our data 
further indicate the specificity of ORF57 in posttran-
scriptional regulation of PAN expression. 
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An MRE at the 5' end of PAN is required for 
ORF57 to accumulate PAN 
 Given ORF57-specific association with PAN 
sequences that could be clustered at three major re-
gions, a 5'-end region (nt 28667-28750), an internal 
region (nt 28971-29114), and a 3'-half region (nt 
29544-29658) (Supplementary Material: Fig. S1), we 
constructed a series of PAN deletion mutants (Fig. 
2A) and evaluated the relevance of these 
ORF57-binding sequences on PAN accumulation in 
the presence or absence of ORF57 by cotransfection of 
HEK293 cells. As shown in Fig. 2B, we demonstrated 
that wt PAN, Δ2 mt with deletion of the internal re-
gion, and Δ3b mt with partial deletion of the 3'-half 
region were all higher responders to ORF57, despite a 
minor reduction of PAN expression observed in two 
mutants in the presence of ORF57. Deletion of the 
5'-end region was detrimental and greatly reduced the 
response of PAN to ORF57 function. Interestingly, 
deletion of the entire 3'-half region (Δ3 mt) including 
the ENE only had a small (~ 2 fold) effect on PAN to 
ORF57. From this analysis, we concluded that the 
5'-end region is essential for PAN RNA accumulation 
and it contributed at least 25-fold enhancement of 
PAN expression in the presence of ORF57 (Figure 2B). 
The ENE is a much weaker element in response to 
ORF57 and the internal region examined in the pres-
ence of ORF57 did not play a significant role in PAN 
expression. As a result, we designated the 5'-end re-
gion of PAN as a functional MRE.  
 
Fig. 2. ORF57-mediated enhancement of PAN expression depends on a 5' PAN element. Shown in (A) are schematic 
diagrams of wt PAN and its deletion mutants. Shaded and numbered boxes represent the positions of ORF57 interacting 
regions identified by CLIP in PAN: box 1 (black), a PAN 5' region from nt 28667-28750; box 2 (dark grey), a PAN internal 
region from nt 28971-29114; box 3 (hatched and solid grey), a PAN 3' region from nt 29544-29658 including the entire ENE 
(hatched grey, nt 29554-29632). Total RNA from HEK293 cells transfected with each of the PAN constructs in the presence 
(+) or absence (-) of ORF57 was examined by Northern blot with a T7 probe for PAN expression (B). The same membrane 
in each panel was stripped and reprobed separately with a 32P-labeled ORF57 or GAPDH probe for ORF57 expression and 
sample loading. Relative levels of PAN RNA in each sample were shown at the bottom of each Northern blot panel after 
normalization to the level of the corresponding GAPDH for sample loading. 
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PAN stability depends on both ORF57 and 
MRE 
 To further analyze the function of the MRE, we 
first evaluated the stability of PAN with or without 
the identified MRE in the presence or absence of 
ORF57. After inhibiting Pol II transcription in HEK293 
cells by treating with actinomycin D, we measured the 
remaining PAN RNA level over the time by RT-qPCR 
and the PAN RNA level was normalized to the cor-
responding GAPDH RNA level for sample loading. 
As shown in Fig. 3, PAN, under our experimental 
conditions, was relatively unstable, with a half-life of 
3.87 h in the absence of ORF57. However, in the 
presence of ORF57, PAN became a significantly more 
stable transcript, with a half-life of 12.2 h, equating to 
a ~3-times longer half-life compared to its absence of 
ORF57. Interestingly, this significant (P=0.005) in-
crease in decay rate of PAN by ORF57 was greatly 
decreased when the MRE was deleted from PAN. In 
the presence of ORF57, PANΔ1 with deletion of the 
MRE (Fig. 3) had a half-life of only 4.78 h, with the 
decay rates being significantly different than wt PAN 
under the same condition (P=0.042). The determined 
half-life (½ = 4.78 h) of the mt PAN in the presence of 
ORF57 was comparable with the half life (½ = 3.87 h) 
of wt PAN in the absence of ORF57, indicating that 
ORF57 enhances PAN expression by stabilizing PAN 
RNA through interaction with the MRE in the 5' re-
gion of PAN. 
 
Fig. 3. Stability of PAN depends on MRE and ORF57. (A) Calculation of half life of wt PAN and mt PANΔ1 lacking the 5' MRE 
in the presence or absence of ORF57. HEK293 cells were transfected with a vector expressing wt or mt PAN together with 
ORF57 or a vector control. 24 h after transfection, transcription was stopped by addition of 10 μg/ml of actinomycin D and 
total RNA was extracted from each sample collected over the time as indicated. PAN and GAPDH (for normalization) were 
quantified by qRT-PCR. The remaining level of PAN RNA in each time point relative to time zero was determined as de-
scribed in Methods, after normalization to GAPDH RNA for sample loading. Results are presented as mean, minimum and 
maximum. A non-linear regression analysis on the raw data was performed, choosing an exponential decay model [Fold 
Percent = α*exp(β*time) ] where α (alpha) is the intercept when time = 0, and β (beta) is the decay rate. (B) Summary of the 
estimated betas (Est. β) and its standard errors (SE) for each study group. Also included are the adjusted R-squares and 
calculated half-life for each study group as well as two-tailed p-values for the indicated pair-wise comparisons between the 
estimated parameters. The p-values for the estimated betas were adjusted using a step-down Bonferroni method. 
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A 9-nt core in the MRE motif II (MRE-II) is 
necessary for ORF57-mediated PAN accumu-
lation 
 By alignment of all MRE sequence tags identi-
fied by ORF57 CLIP assays (Supplementary Material: 
Fig. S1A) in combination with RNA folding analysis, 
we found that the 84-nt MRE is composed of three 
stem-loop structures which were designated as 
MRE-I, -II and III in the 5' to 3' order (See Fig. 4A for 
underlines and 4B for labels). Subsequently, we con-
structed a series of successive 5' to 3' deletions of the 
MRE into the MRE-I (ΔMRE-a), the MRE-I plus the 
MRE-II (ΔMRE-c) and an internal deletion of the en-
tire MRE-II (ΔMRE–d) in the context of PAN (Fig. 4A). 
By cotransfection of HEK293 cells in the presence or 
absence of ORF57, as shown in Fig. 4C and 4D, wt 
PAN expression increased almost 30-fold by ORF57 
when compared to its absence of ORF57, as expected. 
The expression of ΔMRE-a, with complete deletion of 
the MRE-I, also exhibited 34-fold increased PAN ex-
pression in the presence of ORF57 (Fig. 4C), whereas 
the expression of ΔMRE-c, with deletion of both 
MRE-I and entire MRE-II, showed a significant re-
duction in PAN expression when ORF57 was present 
(Fig. 4D). The expression level of PAN from the 
ΔMRE-c (Fig. 4D) was similar to that observed in the 
MREΔ1 mutant in the presence of ORF57 (Fig. 2). 
Collectively, these data indicate that the PAN MRE-II 
is the element through which ORF57 functionally 
modulates PAN expression. The importance of the 
MRE-II in ORF57-mediated PAN expression was 
further verified using an additional construct 
ΔMRE-d, containing an internal deletion of the entire 
MRE-II (Fig. 4A and 4D). The level of PAN ΔMRE-d 
expression observed was comparable to that found for 
ΔMRE-c. 
 As ORF57 appears to preferentially interact with 
a single-stranded loop structure in the vIL-6 MRE [27] 
and other targeted RNAs (our unpublished data), and 
the PAN MRE-II contains an 11-nt loop, we next in-
troduced random point mutations into the MRE-II 
loop. The result was the creation of an MRE-PM (Fig. 
4A and 4B), and we tested its expression in HEK293 
cells along with wt PAN, ΔMRE-c and ΔMRE-d.The 
MRE-PM, with substitution of the 9 nts in the MRE-II 
loop, was impotent to respond to ORF57, when com-
pared with wt PAN and had a similar expression level 
observed for both the ΔMRE-c and ΔMRE-d con-
structs (Fig. 4D). Our results indicate that the 9 nts 
(UAUGGAUUU) in the MRE-II loop function as an 
MRE core for ORF57 interaction in enhancing PAN 
expression. 
 To rule out any transcriptional effect caused by 
the CMV promoter in the tested PAN constructs, we 
replaced the CMV promoter from the CMV-PAN 
constructs with a native PAN promoter and evaluated 
ORF57 regulation of PAN expression from its native 
promoter in HEK293 cells (Fig. 4E, pJM53 for wt PAN 
and pJM54 for mt PAN [MRE-PM]). KSHV ORF50 
(Rta) was used to transactivate PAN expression from 
its native promoter [30,47] in the presence or absence 
of ORF57. In the absence of KSHV Rta, the CMV 
promoter maintained the ability to drive PAN ex-
pression, whereas the native promoter did not (Fig. 
4E, compare lane 3 to lane 1). Consistent with previ-
ous work [30,47], wt PAN, but not its mutant, could 
be transactivated in a dose-dependent manner from 
its native promoter by Rta in the absence of ORF57 
(Fig. 4E, compare lane 4 to lanes 6, 8, 10, 12, 14, and 
16). However, the expression of Rta-transactivated wt 
PAN, but not its mutant, from the native promoter 
could be remarkably increased in the presence of 
ORF57 (Fig. 4E, compare lanes 5 to 7, lanes 9 to 11, and 
lanes 13 to 15). Our data indicate that the identified 
9-nt core in the MRE-II is indeed a functional core in 
the context of PAN and its native promoter. Moreo-
ver, Rta in a high dose (1000 ng) was found to trans-
activate the expression of wt PAN, but not the mt 
PAN, to a prominent level (Fig. 4E, compare lane 14 to 
lane 16) in the absence of ORF57, suggesting instabil-
ity of the mt PAN lacking the 9-nt core in the MRE-II 
even when the PAN promoter is highly active. To-
gether, we conclude that, regardless of the promoter 
used or its transcription efficiency, a functional 
MRE-core in PAN RNA is essential for stabilization of 
PAN RNA and for interaction with ORF57. 
PAN MRE displays a limited function in the 
context of heterologous transcripts 
 To determine whether the PAN MRE can func-
tion in the context of a heterologous transcript, we 
examined PAN expression using the vGPCR con-
struct, an ORF57 insensitive responder (Fig. 1C). We 
first introduced either the entire MRE or the MRE-II 
upstream of the vGPCR sequence (Fig. 5A) to mimic 
its native position in PAN and found, in cotransfected 
HEK293 cells, that the vGPCR, regardless of whether 
accompanied with the insertion of the MRE-II (sense 
or antisense [as]) or the entire MRE, remained to be 
insensitive to ORF57(Fig. 5B). A minimal increase (~3 
fold) of vGPCR RNA expression in the presence of 
ORF57 was found in all vGPCR expression vectors 
with or without insertion of the MRE (compare pJM6 
to pJM18) and was independent of the MRE-II orien-
tation (compare pJM12 to pJM13).  
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Fig. 4. Motif II (MRE-II) of the PAN 5' MRE is necessary for ORF57 enhancement of PAN expression. (A) Schematic diagrams 
of the 5' MRE and its mutants. Shown on the top indicates an 84-bp MRE in the 5' PAN which contains three potential motifs 
(stem-loops) marked as I, II and III, with the sequences underlined. A series of successive 5' to 3' deletions in the 5' MRE, an 
internal deletion or point mutations in the MRE-II are shown as ΔMRE-a, -c, -d and MRE-PM. Nucleotide substitutions in the 
MRE-II sequence in an MRE-PM mutant are boxed. (B) Predicted secondary structures of the MRE. On the left is the 
secondary structure of wt MRE with a folding energy of -19.5 Kcal/mol, consisting of 3 stem-loops I, II, III as described in (A). 
On the right show the point mutations introduced into the MRE-II loop to create an MRE-PM construct. (C, D) Mapping of 
a 9-nt core in the MRE-II responsible for ORF57 enhancement of PAN expression. Total RNA of HEK293 cells transfected 
separately with an indicated PAN construct in (A), together with an ORF57 expression vector (+) or an empty vector (-) was 
examined for PAN expression by Northen blot with a 32P-labeled T7 probe. (E) The MRE element in the presence of ORF57 
promotes PAN accumulation in the context of its native promoter. The upper panel show schematic diagrams of PAN 
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expression driven by a CMV promoter (pJM1) or by a native PAN promoter (PANPr) (pJM53 for wt PAN and pJM54 for mt 
PAN [MRE-PM]). HEK293 cells transfected with each of these constructs in the presence (+) or absence (-) of ORF57 were 
analyzed for PAN expression by Northern blot with a 32P-labeled PAN-specific probe oJM7 (Supplementary Material: Table 
S2). Relative PAN expression levels (fold) were quantified based on the density of each band after normalization to GAPDH 
for sample loading and were shown at the bottom of each blot, with the PAN level in the absence of ORF57 in (C, D) as 1 for 
each PAN construct and wt PAN level in the absence of both ORF57 and ORF50 in (E) as 1 for comparison. 
 
 
 
Fig. 5. The identified PAN MRE does not function efficiently in the expression of heterologous genes vGPCR and Luciferase. 
(A) Schematic diagrams of the vGPCR constructs. The MRE-II motif or the entire MRE was inserted upstream of vGPCR 
(pJM6, Fig. 1C) either in the sense or antisense (As) orientation as indicated by the arrow. (B) Effect of the MRE on vGPCR 
expression in the presence or absence of ORF57. Total RNA of HEK293 cells transfected with each of the constructs in (A), 
together with an ORF57 expressing vector (ORF57 +) or an empty vector (-), was examined for vGPCR expression by 
Northern blot with a 32P-labeled T7 probe. Relative vGPCR expression level (fold) is shown at the bottom of Northern blots 
after normalization to GAPDH. (C) Schematic Diagrams of the firefly luciferase constructs. The entire MRE and/or ENE 
elements were inserted upstream (MRE) or downstream (ENE) of the firefly luciferase ORF, respectively, to mimic their 
native locations in PAN. (D) Effect of the MRE on luciferase expression in the presence or absence of ORF57. HEK293 cells 
were cotransfected with each firefly luciferase reporter construct, together with a Renilla luciferase pRL-TS construct [42] 
and a FLAG-tagged ORF57 expressing vector or an empty FLAG vector (FLAG). 24 h after transfection cells were lysated 
and luciferase activity was measured by a dual luciferase assay. Relative luciferase activity in each sample was calculated by 
dividing the light unit readings obtained from a tested firefly luciferase reporter construct by the light unit readings obtained 
from the Renilla luciferase reporter (F/R ratio). Luciferase activities (mean ± 95% confidence limits) from a mixed model 
analysis of variance are presented along with an adjusted two-tailed p-value. 
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 Given that MRE functions in PAN containing an 
ENE on the 3' end, we then examined the MRE action 
in the context of the PAN ENE in different luciferase 
reporters as diagramed in Fig. 5C. The first set (Set 1) 
of the expression vectors were derived from a 
pMIR-REPORT-Luciferase vector, with the MRE up-
stream and the ENE downstream of the firefly lucif-
erase ORF. A Renilla luciferase for dual luciferase as-
says was expressed from a separate reporter, pRL-TS 
[42]. The second set (Set 2) of expression vectors not 
diagramed in Fig. 5C was derived from a psiCHECK2 
vector expressing both Renilla luciferase and firefly 
luciferase from the same vector, with the MRE (sense 
for pJM47 or antisense for pJM48) upstream and/or 
the ENE (sense for pJM49 or antisense for pJM50) 
downstream of the Renilla luciferase ORF. When each 
of the set 1 reporters was transfected into HEK293 
cells, together with a Renilla luciferase reporter 
pRL-TS and a FLAG-ORF57 or empty FLAG vector 
(Fig. 5D), the PAN-MRE upstream (pJM19), but not 
the PAN ENE downstream (pJM43), of the lucifease 
ORF was found to increase (P=0.011) luciferase activ-
ity only in the presence of ORF57. Under the same 
condition, no synergistic effect was seen for the MRE 
upstream and the ENE downstream of luciferase on 
the same vector (pJM44) (Fig. 5D). These data indicate 
that the PAN MRE could function weakly in a se-
lected heterologous transcript in the presence of 
ORF57 and other sequence motif(s) in PAN other than 
the ENE are needed for the MRE to fully function. 
This interpretation was further verified in 
Dox-induced TREx BCBL1-Rta cells by transfection of 
the set 2 expression vectors (data not shown).  
A 9-nt core in the MRE-II loop interacts with 
ORF57, PABPC1 and E1B-AP5 
 As shown in Fig. 4, PAN stability requires a 
functional MRE-II and ORF57. To provide direct bio-
chemical evidence of the 9-nt core RNA interacting 
with ORF57 protein, we performed a biotinylat-
ed-RNA pull-down assay [27,43] using a series of bio-
tinylated RNA oligomers covering the entire PAN 
MRE-II and MRE-III (oJM32, oJM33, oJM34, oJM35) 
(Fig. 6A). RNA oligomers from the MRE-I stem-loop 
were excluded since deletion of this stem-loop from 
PAN did not affect PAN accumulation in response to 
ORF57 (ΔMRE-a in Fig. 4A and 4C). When these RNA 
oligomers were compared in pulling down ORF57 
expressed from Dox-induced TREx BCBL1-Rta cells, 
the oJM35 oligomer which covers the entire 9-nt core 
of MRE-II loop was found to efficiently bind ORF57 in 
a level comparable to an vIL-6 RNA oligomer oNP42, 
a positive ORF57-binding oligomer [27], but all other 
oligomers showed less binding affinity to ORF57 (Fig. 
6A).  
 Subsequently, oJM35 was used to search for 
ORF57 protein partners capable of binding to the 
MRE. Proteins pulled down with oJM35 from total cell 
extract of Dox-induced TREx BCBL1-Rta cells was 
identified by Nano LC-MS/MS peptide sequencing 
technology. We found oJM35 interacting efficiently 
with cellular PABPC1 and a heterogeneous nuclear 
ribonucleoprotein E1B-AP5 (E1B 
55-kilodalton-associated protein or hnRNPUL1). This 
could be further verified by RNA pulldown and 
Western blot analyses (Fig. 6B), showing that only 
oJM35 containing an intact 9-nt core in the MRE-II 
could interact efficiently with ORF57 and PABPC1 
from TREx BCBL1-Rta cell extract (Fig. 6B, compare 
lane 4 to lane 5). Other RNA oligomers oJM32, oJM33 
and oJM34 do not have a 9-nt core and showed less 
affinity to these three proteins (Fig. 6B, compare lanes 
1-3 to lane 4). However, oJM35 appeared to interact 
with E1B-AP5 independently of ORF57 because it 
bound E1B-AP5 in TREx BCBL1-vector cells express-
ing no ORF57 (Fig. 6B, compare lane 4 to lane 5). A 
reduced level of E1B-AP5 interaction with oJM35 in 
the pulldowns with TREx BCBL1-Rta cell extract (R) 
than with TREx BCBL1-vector cell extract (V) (Fig. 6B, 
compare lanes 4 to 5 and lanes 9 to 10) suggests a re-
duced expression of E1B-AP5 in TREx BCBL1-Rta 
cells (Fig. 6B, compare lane 17 to 18 for the input). 
More importantly, we found that PABPC1, similar to 
ORF57, bound wt MRE-core RNA (oJM35), but not its 
mutant form (oJM68) (Fig. 6B, compare lines 4-5 and 
9-10 to lanes 11-12), which is in contrast to E1B-AP5 
binding both wt and mt RNA oligomers. The oJM68 
has the same sequence as oJM35, but its 9-nt core 
UAUGGAUUU was changed to CUGCACGUC and 
this mutation in the context of PAN gene was suffi-
cient to inactivate PAN expression in response to 
ORF57 (Fig. 4D and 4E). In addition, we found that 
PABPC1 binding to oJM35 took place more efficiently 
with the ORF57 expressing cell extract than with the 
ORF57 lacking one, but its binding to oNP42, a vIL-6 
MRE-derived RNA oligomer [27], could be found for 
both cell total extracts independent of the ORF57 
presence (Fig. 6B, compare lanes 4-5 and 9-10 to lanes 
13-14), suggesting PABPC1 as an ORF57 partner pro-
tein specific in PAN MRE-II interaction.  
PAN RNA is exportable in the presence of 
ORF57 
 PAN was initially discovered as a nuclear 
non-coding RNA [28,32]. In chemical-induced BCBL1 
cells with ORF57 expression, we found that PAN 
RNA was partially exported, resulting in ~20% of 
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PAN RNA in the cytoplasm (Fig. 7A). This was spe-
cially true when PAN RNA was expressed in HeLa 
cells and HEK293 cells. By careful fractionation of 
HeLa cells and HEK293 cells with cotransfection of 
ORF57 and PAN as shown in Fig. 7B and 7C, a small 
fraction (~30%) of wt PAN were found in the cyto-
plasmic fraction of both HeLa (compare lane 2 to lane 
3 in Fig. 7B) and HEK293 (compare lane 1 to lane 2 in 
Fig. 7C) cells in the presence of ORF57. The similar 
results were also obtained from both cell lines by us-
ing a PANΔ3 mutant (see Fig. 2A) with deletion of the 
entire 3'-half region including the ENE (compare lane 
14 to lane 15 in Fig. 7B and lane 5 to lane 6 in Fig. 7C). 
Together, these data suggest a likelihood consequence 
of nuclear PAN accumulation in the presence of 
ORF57.  
 
 
 
Fig. 6. MRE-II RNA interacts in vitro with ORF57 and other cellular proteins. (A) Mapping of an MRE binding site for ORF57. 
Shown on the top is a PAN MRE sequence lacking the MRE-I region in Fig. 4A, with the 9-nt core of MRE-II loop sequence 
bolded and underlined and the nt positions of biotinylated RNA oligomers employed in RNA pull-down assays. A cell lysate 
prepared from TREx BCBL-1-Rta cells [39] induced with Dox for 24 h was used for the RNA pulldown assays with an 
indicated RNA oligomer. The RNA oligo oNP42 derived from vIL-6 RNA [27] which binds ORF57 was used as a positive 
control. ORF57 associated with RNA oligos in the pulldowns was immunoblotted using an anti-ORF57 antibody. The cell 
lysate (10%) before the pulldown was loaded as a Western blot control. (B) Biotinylated RNA affinity pulldown analysis by 
Western blot using anti-ORF57, PABPC1 and E1B-AP5 antibodies. Total cell extract from TREx BCBL-1-Rta (R) or -vector 
(V) cells induced by Dox for 24 h was used for the RNA pulldown assays with each biotinylated RNA oligomer. RNA oligos 
oNP41 and oNP42 derived from vIL-6 RNA [27] were used, respectively, as a negative and positive oligomer control for 
ORF57 interaction and 10% of the cell lysate from each cell line before the pulldown was loaded for Western blotting 
control. RNA oligo oJM68 is a copy of oJM35 with the point mutations in the MRE-II loop described in Fig. 4B. Control beads 
indicate no RNA oligomer on the beads.  
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Fig. 7. A small proportion of PAN are exportable in ORF57-coexpressing cells. Total (T) and fractionated cytoplasmic (C) 
or nuclear (N) RNA from BCBL1 cells treated with or without valproate (VA, 1 mM) for viral lytic induction (A) or from 
HeLa cells (B) cotransfected with pJM1 (wt PAN), pJM2 (mt PANΔ1), or pJM4 (mt PANΔ3) in the presence (ORF57+) or 
absence (an empty vector control, ORF57-) of ORF57, were examined by Northern blot for PAN RNA expression. HEK293 
cells cotransfected with pJM1 (wt PAN), pJM2 (mt PANΔ1), or pJM4 (mt PANΔ3) in the presence of ORF57 were also 
fractionated and examined by Northern blot for PAN RNA expression (C). GAPDH RNA served as a control for sample 
loading and U6 RNA served as a fractionation efficiency control. The relative levels of PAN in each sample were calculated 
after normalization to GAPDH. 
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Discussion 
 We previously developed a high-throughput 
and genome-wide CLIP assay as a powerful tool to 
study ORF57 protein-RNA interactions in living cells 
[27]. This CLIP assay allowed us to identify PAN 
RNA as the main target of ORF57. In this report we 
show that ORF57 binds to a 9-nt core sequence 
(UAUGGAUUU, KSHV nt 28704-28712) in the loop 
structure of the PAN MRE-II to promote PAN accu-
mulation by increasing its half-life. Moreover, we 
found that the PAN MRE-II also interacts with 
PABPC1 and E1B-AP5. More specifically, the 9-nt core 
sequence in the PAN MRE-II was identified for the 
binding of PABPC1, but not for E1B-AP5 [48], sug-
gesting that these two proteins by binding to different 
regions of the MRE-II may form a stable protein-RNA 
complex with ORF57 in accumulation of PAN RNA. 
Recently, we showed that ORF57 stabilizes ORF59 
RNA by preventing aberrant ORF59 polyadenylation 
[26] and promotes the expression of vIL-6 and cellular 
IL-6 by preventing interactions of vIL-6 and cellular 
IL-6 RNAs with miR-1293 or miR-608, respectively 
[27]. In this report, we showed that another function 
of ORF57 is to prolong RNA half-life by binding to a 5' 
PAN MRE. Together with folding of all ORF57 CLIP 
sequences published in our previous report [27], these 
studies clearly indicate that ORF57 binding is RNA 
structure- and context-dependent and requires alter-
native proteins and different response elements to 
function. 
 Although our CLIP assays identified three re-
gions of PAN RNA, including a 3' region encom-
passing the ENE previously reported in other studies 
[34-36], in association with ORF57 [27], this study 
demonstrated that only the 5' end of PAN operates as 
a functional MRE in ORF57-mediated PAN accumu-
lation. Deletion of other putative MREs from the in-
ternal region or the 3' region of PAN, including the 
ENE, had only a minimal effect on ORF57-mediated 
PAN accumulation. When inserted into the 5' UTR 
region of an ORF57 non-responding viral transcript 
vGPCR, however, the 84-nt MRE identified from the 
PAN 5' end was unable to efficiently promote accu-
mulation of the tested RNAs in the presence of 
ORF57. This indicates that other regions associated 
with ORF57, albeit not being important for ORF57 
accumulation of PAN, might be needed to act as an 
auxiliary element to convert an ORF57 non-responder 
to an ORF57 responder. Moreover, further insertion of 
a 79-nt ENE to the 3' UTR of a luciferase transcript 
containing a PAN MRE in its 5' UTR did not provide 
additional effect to the PAN MRE on luciferase activ-
ity. Thus, the biological relevance of ORF57 binding to 
other PAN regions remains to be understood. 
 Consistent with our observations, a recent study 
also reported by deletion mutation analysis that 
ORF57 binds to a ~300-nt region (ORE) located on the 
5' end of PAN RNA that was responsible for PAN 
accumulation [38]. By using a PAN-Δ79 (ΔENE) mu-
tant, ORF57 was proven to protect the mutant from 
RNA decay. Whether ORF57 also affects wt PAN 
half-life was not included in the report [38]. As we 
stated in Fig. 2 that ORF57 also binds to the ENE re-
gion in our CLIP assays and deletion of this region 
decreased ORF57 effect on PAN accumulation only by 
2-fold. In our study, both wt PAN and mt PANΔ1 
lacking the MRE were examined and ORF57 was 
found to greatly prolong the wt PAN half-life from 
3.87 h to 12.2 h, but was impotent for the mt PANΔ1 
lacking the MRE-II (Fig. 3). Our results also differ 
from Sahin’s report [38] on the roles of the identified 
MRE in heterologous reporters. We were unable to 
find the functional 89-nt MRE being greatly active in 
the 5' UTR region of vGPCR or luciferase RNA in re-
sponse to ORF57. Although the ~300-nt ORE inserted 
to the β-globin 3' end was able to increase the β-globin 
response to ORF57 by 4-fold in Sahin’s study [38], we 
noticed that an approximate 3-fold increase of a re-
porter gene expression in the presence of ORF57 is 
common almost for any testing system. An RNA 
transcript with this level increase in the presence of 
ORF57 was viewed as an ORF57 non-responsive 
transcript, such as vGPCR, K5 and luciferase when 
compared with PAN which showed a ~30-fold in-
crease in the presence of ORF57 in this report. Alter-
natively, the difference may be due to a larger piece of 
the ORE insertion at the 3' end of β-globin in Sahin’s 
study that put the testing ORE different from its na-
tive location in the PAN. 
 PABPC1 is a cytoplasmic protein involved in 
mRNA translation initiation and stability [49-52]. 
When shuttled to the nucleus, PABPC1 engages in 
nuclear RNA biogenesis [50,53,54]. In this study, we 
found that PABPC1 also binds to the 9-nt core of PAN 
MRE-II. E1B-AP5 or HNRNPUL1 (heterogeneous nu-
clear ribonucleoprotein U-like 1) has been implicated 
in the export of cellular mRNAs [48] by interacting 
with export protein TAP [55]. In addition, E1B-AP5 
activates transcription [56], binds p53 [57] and par-
ticipates in DNA damage signaling pathways [58]. We 
found that E1B-AP5 interacts with the PAN MRE-II 
motif outside of the 9-nt core in the MRE-II loop, in-
dicating that E1B-AP5 binds to a different region in 
the MRE-II from PABPC1. Whether the binding of 
these two proteins to the PAN MRE-II is also im-
portant for ORF57 accumulation of PAN is under ac-
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tive investigation. Nevertheless, our data clearly 
suggest that PABPC1 and E1B-AP5 may modulate 
PAN expression in complex with ORF57.  
Supplementary Material 
Fig.S1: Alignments of the CLIP sequences to PAN in 
ORF57 CLIP assays. Table S1: The list of all plasmids 
constructed or used in this study.  Table S2: The list of 
oligos used in this study.   
http://www.biolsci.org/v07p1145s1.pdf 
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